Pharmazz is a privately held company developing novel products in critical care medicine. The U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke. In addition, Pharmazz obtained marketing authorization for two of its first-in-class drug molecules, Centhaquine and Sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. Pharmazz has partnered with Sun Pharmaceutical to market Sovateltide for cerebral ischemic stroke patients in India. In addition, Pharmazz has partnered with Dr. Reddy's Laboratories to market Centhaquine, a resuscitative agent, in India. Additional information may be found on the Company's website, www.pharmazz.com.
Company Details
- Employees
- 39
- Founded
- -
- Address
- 50 West 75th Street,
- Phone
- +1 (630)780-6087
- in****@****azz.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- pharmazz.com
- Keywords
- Critical Care Medicine, Neurology, COVID-19.
- HQ
- IL
Pharmazz Inc. Questions
Pharmazz Inc.'s helpline number is +1 (630)780-6087
Pharmazz Inc.'s website is pharmazz.com
Pharmazz Inc.'s LinkedIn profile is https://www.linkedin.com/company/pharmazz
Pharmazz Inc. has
39 employees.
View email and phone details for 39
employees at Pharmazz Inc..
Pharmazz Inc.'s industry is
Pharmaceutical Manufacturing
Pharmazz Inc.'s top competitors are
Clinexel,
32 Biosciences "three Squared",
Tech Observer,
Apex - Spacecraft Manufacturing,
Clinisapiens Research Services Private Limited,
Insights Opinion,
Orisdx,
Bristol Myers Squibb,
Tata 1mg,
Innovate Research.
Pharmazz Inc.'s support email address is info@pharmazz.com
Pharmazz Inc.'s categories are Pharmaceutical Manufacturing
Pharmazz Inc.'s founding year is 2010
